Archived Monthly Oncology Tumor Boards: Treatment of Patients with Kidney Cancer

Adjuvant treatment options for patients with advanced renal cell carcinoma (RCC) following surgery are continually evolving, and new treatment options for different stages of RCC are being approved. Immunotherapies are gaining impetus as promising adjuvant treatment for patients with RCC with high-risk of relapse and clinicians would benefit from the education of relevant clinical trial data behind these therapies. The repertoire of systemic therapies is rapidly expanding, and a review of risk stratification and disease classification to strategies treatment is of interest. It can be challenging for clinicians to remain up-to-date on these rapidly evolving updates.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the clinical outcomes of recent studies evaluating new therapies for adjuvant treatment of renal cell carcinoma (RCC) at intermediate/high or high risk or relapse following nephrectomy.
  • Review the recent updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer and how they may be incorporated into clinical practice.
  • Describe approaches for treatment decision-making for patients with relapsed or stage IV RCC and how to strategize systemic treatment options as first- and second-line therapies.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Coherus BioSciences
  • Exact Sciences
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis

This activity is supported by independent educational grants from:

  • Merck & Co., Inc.
  • Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
10/28/2022
Course expires: 
10/28/2023
Cost:
$0.00
Part of: 
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center

Surena F. Matin, MD
The University of Texas MD Anderson Cancer Center

Chad Tang, MD
The University of Texas MD Anderson Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Eric Jonasch, MD
Aravive: Consulting Fee
Arrowhead Pharmaceuticals, Inc.: Grant/Research Support
AVEO Pharmaceuticals, Inc.: Consulting Fee
Calithera Biosciences, Inc.: Consulting Fee
Eisai Inc.: Consulting Fee
Exelixis Inc.: Consulting Fee
Ipsen: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
NiKang Therapeutics, Inc.: Consulting Fee; Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Surena F. Matin, MD
Elsevier: Honoraria
Johnson & Johnson/Janssen: Consulting Fees
Merk & Co., Inc.: Consulting Fees
QED Therapeutics: Grant/Research Support 

Chad Tang, MD
Bayer HealthCare: Consulting Fees
Diffusion Pharmaceuticals, Inc.: Scientific Advisor

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-22-110-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 28, 2023. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00052507; Approval #: 220003354

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing